Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. The company is headquartered in Irvine, California and currently employs 2,200 full-time employees. The company went IPO on 2007-08-08. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The company primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others.
根據最新的財務報表(Form-10K),Swedish Orphan Biovitrum AB (publ) 的總資產為 $0,淨isProfitable}為 $0
MASI 的關鍵財務比率是什麼?
Swedish Orphan Biovitrum AB (publ) 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
Masimo Corp 的收入按細分市場或地理位置如何劃分?
Swedish Orphan Biovitrum AB (publ) 最大收入來源為 Haematology,在最近的收益報告中收入為 13,370,000,000。就地區而言,United States 是 Swedish Orphan Biovitrum AB (publ) 的主要市場,收入為 8,148,000,000。
Masimo Corp 是否盈利?
無,根據最新的財務報表,Swedish Orphan Biovitrum AB (publ) 的淨損失為 $0